Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Bicara Therapeutics (Nasdaq: BCAX) awarded an inducement non-qualified stock option on March 2, 2026 to a new employee for 115,000 shares at an exercise price of $17.59, equal to the Nasdaq closing price that day.

The award vests 25% after one year, then in 12 equal quarterly installments, was granted under Bicara’s 2026 Inducement Plan (adopted January 2026) and approved by the compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).

News Market Reaction – BCAX

+3.46%

3 alerts

+3.46% News Effect

+$35M Valuation Impact

$1.06B Market Cap

0.1x Rel. Volume

On the day this news was published, BCAX gained 3.46%, reflecting a moderate positive market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $35M to the company's valuation, bringing the market cap to $1.06B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Inducement option grant: 115,000 shares Exercise price: $17.59 per share Par value: $0.0001 per share +4 more

7 metrics

Inducement option grant 115,000 shares Non-qualified stock option granted on March 2, 2026 to one new employee

Exercise price $17.59 per share Equal to BCAX Nasdaq closing price on March 2, 2026

Par value $0.0001 per share Par value of Bicara’s common stock referenced in grant

Initial vesting tranche 25% of shares One-fourth vests on first anniversary of employee’s start date

Subsequent vesting schedule 12 equal quarterly installments Remaining options vest quarterly after first anniversary, contingent on service

Listing rule Nasdaq Rule 5635(c)(4) Grant made as a material inducement to employment under this rule

Grant date March 2, 2026 Date inducement option was awarded under 2026 Inducement Plan

Market Reality Check

Price: $18.54 Vol: Volume 560,064 is slightl...

normal vol

$18.54 Last Close

Volume Volume 560,064 is slightly above the 20-day average of 514,483 ahead of this filing-focused news. normal

Technical Shares at $17.92 are trading above the 200-day MA of $14.11 and about 9% below the 52-week high of $19.71.

Peers on Argus

Sector peers showed mixed moves, with TYRA in the momentum list trading down and...

1 Up 1 Down

Sector peers showed mixed moves, with TYRA in the momentum list trading down and ANAB trading up. With only one peer in each direction and BCAX’s move not flagged, trading appears more stock-specific than part of a broad biotech rotation.

Historical Context

5 past events · Latest: Feb 26 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 26	Offering closing	Neutral	-0.1%	Closed oversubscribed underwritten offering with full exercise of underwriters’ option.
Feb 24	Offering pricing	Negative	+7.8%	Priced $150M public offering of common stock and pre-funded warrants.
Feb 24	Offering launch	Negative	+7.8%	Proposed $150M common stock offering from an effective Form S‑3 shelf.
Feb 23	Investor conferences	Positive	+5.9%	Announced participation in multiple investor conferences with leadership presentations.
Feb 19	Clinical data update	Positive	+0.4%	Reported Phase 1b data for ficerafusp alfa with strong response rates in HNSCC.

Pattern Detected

Recent news clusters around financings and positive clinical data, with offerings sometimes drawing positive reactions and clinical updates generally seeing modest gains.

Recent Company History

Over the last few weeks, Bicara has combined positive clinical updates with significant financing activity. On Feb 19, Phase 1b data for ficerafusp alfa in HPV-negative HNSCC showed strong response metrics, followed by an investor conference schedule on Feb 23. From Feb 24–26, the company announced, priced, and closed a large public offering of stock and pre-funded warrants, supported by a subsequent 8-K and insider/major holder filings. Today’s inducement option grant fits into this pattern of equity-related corporate actions.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-10-03

The company has an active Form S-3 shelf registration filed on Oct 3, 2025. It has been used multiple times via 424B5 prospectus supplements, including offerings in late 2025 and February 2026, indicating an established framework for issuing registered securities.

Market Pulse Summary

This announcement details a standard Nasdaq Rule 5635(c)(4) inducement grant: a non-qualified option...

Analysis

This announcement details a standard Nasdaq Rule 5635(c)(4) inducement grant: a non-qualified option for 115,000 shares at $17.59, vesting over time to retain a new hire. It follows a period of sizeable equity offerings and insider-related filings, all under an active Form S-3 shelf. Investors may focus on how such grants fit into overall equity compensation, recent financing activity, and progress of ficerafusp alfa’s clinical and regulatory milestones.

Key Terms

inducement grant, non-qualified stock option, exercise price, vesting, +2 more

6 terms

inducement grant financial

"today announced it awarded an inducement grant on March 2, 2026 to one new employee"

An inducement grant is a stock-based reward given to a new hire—often options or restricted shares—used as a recruiting “signing bonus” to encourage someone to join a company and stay long enough to add value. Investors care because these grants can dilute existing shareholdings, change executive incentives and increase reported compensation costs, so they signal both management priorities and potential impacts on shareholder value.

non-qualified stock option financial

"The employee received a non-qualified stock option to purchase 115,000 shares"

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

exercise price financial

"with an exercise price of $17.59 per share, equal to the closing price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"One-fourth of the shares vest on the first anniversary of the employee’s applicable start date"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

equity incentive plans financial

"award was granted outside of Bicara’s stockholder-approved equity incentive plans"

Equity incentive plans are company programs that pay employees, executives, or directors with company stock, stock options, or share units instead of or in addition to cash, aiming to align their interests with shareholders—like giving team members a stake in the house they help build. For investors this matters because such plans can motivate better company performance but also dilute existing ownership and increase reported compensation costs, so they affect future earnings, voting power, and share value.

Nasdaq Listing Rule 5635(c)(4) regulatory

"as a material inducement to the employee entering into employment with Bicara in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. Not financial advice.

BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awarded an inducement grant on March 2, 2026 to one new employee under Bicara’s 2026 Inducement Plan as a material inducement to employment.

The employee received a non-qualified stock option to purchase 115,000 shares of Bicara’s common stock, par value $0.0001 per share, with an exercise price of $17.59 per share, equal to the closing price of Bicara’s common stock as reported by Nasdaq on March 2, 2026. One-fourth of the shares vest on the first anniversary of the employee’s applicable start date, with the remaining shares vesting in 12 equal quarterly installments thereafter, subject to the employee’s continued service with the company through each applicable vesting date.

The above-described award was granted outside of Bicara’s stockholder-approved equity incentive plans and is pursuant to Bicara’s 2026 Inducement Plan, which was adopted by Bicara’s board of directors in January 2026. The award was approved by the compensation committee of Bicara’s board of directors, which is comprised solely of independent directors, as a material inducement to the employee entering into employment with Bicara in accordance with Nasdaq Listing Rule 5635(c)(4).

About Bicara Therapeutics
Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara’s lead program, ficerafusp alfa, is a first-in-class bifunctional antibody designed to drive tumor penetration by breaking barriers in the tumor microenvironment that have challenged the treatment of multiple solid tumor cancers. Specifically, ficerafusp alfa combines two clinically validated targets: an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β). Through this targeted mechanism, ficerafusp alfa reverses the fibrotic and immune-excluded tumor microenvironment driven by TGF-β signaling to enable tumor penetration that drives deep and durable responses. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types. For more information, please visit www.bicara.com or follow us on LinkedIn and X.

Contacts

Investors:
Jenna Cohen
IR@bicara.com

Media:
Amanda Lazaro
1AB
Amanda@1abmedia.com

FAQ

What did Bicara Therapeutics (BCAX) grant on March 2, 2026?

Bicara granted a non-qualified stock option for 115,000 shares to a new employee. According to the company, the option was issued as a material inducement to employment under its 2026 Inducement Plan.

What is the exercise price and reference date for the BCAX option grant?

The exercise price is $17.59 per share, set equal to the Nasdaq closing price on March 2, 2026. According to the company, that closing price determined the option strike for the inducement award.

How does the vesting schedule work for Bicara's 115,000-share option (BCAX)?

The option vests 25% after one year, then in 12 equal quarterly installments thereafter. According to the company, vesting is subject to continued service through each applicable vesting date.

Under which plan was the Bicara (BCAX) inducement award granted?

The award was granted under Bicara’s 2026 Inducement Plan, adopted by the board in January 2026. According to the company, the grant was outside stockholder-approved equity incentive plans.

Who approved the inducement grant for Bicara Therapeutics (BCAX)?

The compensation committee of Bicara’s board approved the inducement grant. According to the company, the committee is comprised solely of independent directors and approved the award per Nasdaq Rule 5635(c)(4).